journal
https://read.qxmd.com/read/33837047/correspondence-on-impact-of-the-covid-19-pandemic-on-morbidity-and-mortality-in-patients-with-inflammatory-joint-diseases-and-in-the-general-population-a-nationwide-swedish-cohort-study
#1
LETTER
Liang En Wee, Edwin Philip Conceicao, Jing Yuan Tan, Julian Thumboo, Indumathi Venkatachalam
No abstract text is available yet for this article.
April 9, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33832966/eular-points-to-consider-ptc-for-designing-analysing-and-reporting-of-studies-with-work-participation-as-an-outcome-domain-in-patients-with-inflammatory-arthritis
#2
Annelies Boonen, Polina Putrik, Mary Lucy Marques, Alessia Alunno, Lydia Abasolo, Dorcas Beaton, Neil Betteridge, Mathilda Bjørk, Maarten Boers, Boryana Boteva, Bruno Fautrel, Francis Guillemin, Elsa F Mateus, Elena Nikiphorou, Márta Péntek, Fernando Pimentel Santos, Johannes L Severens, Suzanne M M Verstappen, Karen Walker-Bone, Johan Karlsson Wallman, Marieke M Ter Wee, René Westhovens, Sofia Ramiro
BACKGROUND: Clinical studies with work participation (WP) as an outcome domain pose particular methodological challenges that hamper interpretation, comparison between studies and meta-analyses. OBJECTIVES: To develop Points to Consider (PtC) for design, analysis and reporting of studies of patients with inflammatory arthritis that include WP as a primary or secondary outcome domain. METHODS: The EULAR Standardised Operating Procedures were followed...
April 8, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33832965/variants-in-urate-transporters-adh1b-gckr-and-mepe-genes-associate-with-transition-from-asymptomatic-hyperuricaemia-to-gout-results-of-the-first-gout-versus-asymptomatic-hyperuricaemia-gwas-in-caucasians-using-data-from-the-uk-biobank
#3
Gabriela Sandoval-Plata, Kevin Morgan, Abhishek Abhishek
OBJECTIVES: To perform a genome-wide association study (GWAS) of gout cases versus asymptomatic hyperuricaemia (AH) controls, and gout cases versus normouricaemia controls, and to generate a polygenic risk score (PRS) to determine gout-case versus AH-control status. METHODS: Gout cases and AH controls (serum urate (SU) ≥6.0 mg/dL) from the UK Biobank were divided into discovery (4934 cases, 56 948 controls) and replication (2115 cases, 24 406 controls) cohorts...
April 8, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33827788/efficacy-and-safety-of-tofacitinib-versus-baricitinib-in-patients-with-rheumatoid-arthritis-in-real-clinical-practice-analyses-with-propensity-score-based-inverse-probability-of-treatment-weighting
#4
Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Satoshi Kubo, Yoshino Inoue, Yoshihisa Fujino, Yoshiya Tanaka
OBJECTIVES: The differences of efficacy between each Janus kinase (JAK) inhibitors have not been clarified in the patients with rheumatoid arthritis (RA) in clinical practice. Here, we compared the efficacy between tofacitinib (TOFA) and baricitinib (BARI) in clinical practice. METHODS: The efficacy of TOFA (n=156) in patients with RA was compared with BARI (n=138). Selection bias was reduced to a minimum using propensity score-based inverse probability of treatment weighting (IPTW)...
April 7, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33827787/efficacy-and-safety-of-brodalumab-an-anti-il17ra-monoclonal-antibody-in-patients-with-axial-spondyloarthritis-16-week-results-from-a-randomised-placebo-controlled-phase-3-trial
#5
James Cheng-Chung Wei, Tae-Hwan Kim, Mitsumasa Kishimoto, Naoki Ogusu, Haeyoun Jeong, Shigeto Kobayashi
OBJECTIVE: To investigate the efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA). METHODS: In a multicentre, placebo-controlled phase 3 study (NCT02985983) conducted at 48 sites across Japan, Korea and Taiwan, patients with axSpA were randomised 1:1 to receive subcutaneous brodalumab 210 mg (n=80) or placebo (n=79) at baseline, weeks 1 and 2 and every 2 weeks thereafter, during the 16-week double-blind period...
April 7, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33811037/dynamical-trajectory-of-glucocorticoids-tapering-and-discontinuation-in-patients-with-rheumatoid-arthritis-commencing-glucocorticoids-with-csdmards-a-real-world-data-from-2009-to-2020
#6
Wenhui Xie, Hong Huang, Guangtao Li, Yanjie Hao, Yanni Gui, Yu Wang, Xuerong Deng, Juan Zhao, Yan Geng, LanLan Ji, Xiaohui Zhang, Zhibo Song, Zhuoli Zhang
OBJECTIVE: To unravel the dynamical trajectory and features of glucocorticoids (GC) tapering and discontinuation in patients with rheumatoid arthritis (RA) commencing GC with concomitant conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODS: We used data from longitudinal real-world Treat-to-TARget in RA cohort. Patients with RA who started GC and contaminant csDMARDs therapy were included. The changes in GC dose and disease activity were evaluated...
April 2, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33811036/five-year-treat-to-target-outcomes-after-methotrexate-induction-therapy-with-or-without-other-csdmards-and-temporary-glucocorticoids-for-rheumatoid-arthritis-in-the-carera-trial
#7
Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly, Delphine Bertrand, Patrick Verschueren
OBJECTIVES: To compare outcomes of different treatment schedules from the care in early rheumatoid arthritis (CareRA) trial over 5 years. METHODS: Patients with RA completing the 2-year CareRA randomised controlled trial were eligible for the 3-year observational CareRA-plus study. 5-year outcomes after randomisation to initial methotrexate (MTX) monotherapy with glucocorticoid bridging (COBRA-Slim) were compared with MTX step-up without glucocorticoids or conventional synthetic disease-modifying antirheumatic drug (DMARD) combinations with glucocorticoid bridging, per prognostic patient group...
April 2, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33811035/correspondence-on-lupus-or-not-sle-risk-probability-index-slerpi-a-simple-clinician-friendly-machine-learning-based-model-to-assist-the-diagnosis-of-systemic-lupus-erythematosus
#8
LETTER
Ezgi Deniz Batu, Ummusen Kaya Akca, Ozge Basaran, Yelda Bilginer, Seza Ozen
No abstract text is available yet for this article.
April 2, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33811034/effects-of-rankl-inhibition-on-promoting-healing-of-bone-erosion-in-rheumatoid-arthritis-using-hr-pqct-a-2-year-randomised-double-blind-placebo-controlled-trial
#9
Ho So, Isaac T Cheng, Sze-Lok Lau, Evelyn Chow, Tommy Lam, Vivian W Hung, Edmund K Li, James F Griffith, Vivian W Lee, Lin Shi, Junbin Huang, Kitty Yan Kwok, Cheuk-Wan Yim, Tena K Li, Vincent Lo, Jolie Lee, Jack Jock-Wai Lee, Ling Qin, Lai-Shan Tam
OBJECTIVE: To evaluate the effects of denosumab on erosion healing at 2-4 metacarpophalangeal (MCP) head as determined by high-resolution peripheral quantitative CT (HR-pQCT) in patients with rheumatoid arthritis (RA) with stable disease. METHODS: This was a randomised, placebo-controlled, double-blind study. Patients with RA with disease activity score 28 joints (DAS28) ≤5.1 were randomised (1:1) to subcutaneous denosumab 60 mg or placebo once every 6 months for 24 months...
April 2, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33811033/response-to-correspondence-on-lupus-or-not-sle-risk-probability-index-slerpi-a-simple-clinician-friendly-machine-learning-based-model-to-assist-the-diagnosis-of-systemic-lupus-erythematosus-by-batu-et-al
#10
https://read.qxmd.com/read/33811032/response-to-correspondence-on-interleukin-6-receptor-inhibition-in-primary-sj%C3%A3-gren-syndrome-a-multicentre-double-blind-randomised-placebo-controlled-trial-by-de-wolff-et-al
#11
Renaud Felten, Jacques-Eric Gottenberg
No abstract text is available yet for this article.
April 2, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33811031/immune-response-to-dermatomyositis-specific-autoantigen-transcriptional-intermediary-factor-1%C3%AE-can-result-in-experimental-myositis
#12
Naoko Okiyama, Yuki Ichimura, Miwako Shobo, Ryota Tanaka, Noriko Kubota, Akimasa Saito, Yosuke Ishitsuka, Rei Watanabe, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Akihiro Murakami, Hisako Kayama, Kiyoshi Takeda, Manabu Fujimoto
OBJECTIVES: To investigate whether autoimmunity to transcriptional intermediary factor 1 (TIF1)γ, a ubiquitous nuclear autoantigen for myositis-specific autoantibodies detected in patients with dermatomyositis (DM) is pathogenetic for inflammatory myopathy. METHODS: Wild-type, β2 -microglobulin-null, perforin-null, Igμ-null and interferon α/β receptor (IFNAR)-null mice were immunised with recombinant human TIF1γ whole protein. A thymidine incorporation assay was performed using lymph node T cells from TIF1γ-immunised mice...
April 2, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33789873/pathogenic-uba1-variants-associated-with-vexas-syndrome-in-japanese-patients-with-relapsing-polychondritis
#13
Naomi Tsuchida, Yosuke Kunishita, Yuri Uchiyama, Yohei Kirino, Makiko Enaka, Yukie Yamaguchi, Masataka Taguri, Shoji Yamanaka, Kaoru Takase-Minegishi, Ryusuke Yoshimi, Satoshi Fujii, Hideaki Nakajima, Naomichi Matsumoto
OBJECTIVES: To determine clinical and genetic features of individuals with relapsing polychondritis (RP) likely caused by pathogenic somatic variants in ubiquitin-like modifier activating enzyme 1 ( UBA1 ). METHODS: Fourteen patients with RP who met the Damiani and Levine criteria were recruited (12 men, 2 women; median onset age (IQR) 72.1 years (67.1-78.0)). Sanger sequencing of UBA1 was performed using genomic DNA from peripheral blood leukocytes or bone marrow tissue...
March 31, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33789872/response-to-correspondence-on-what-comes-after-the-lockdown-clustering-of-anca-associated-vasculitis-single-centre-observation-of-a-spatiotemporal-pattern-by-hocevar-et-al
#14
Philipp Gauckler, Erica L Bettac, Andreas Kronbichler
No abstract text is available yet for this article.
March 31, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33789871/correspondence-on-what-comes-after-the-lockdown-clustering-of-anca-associated-vasculitis-single-centre-observation-of-a-spatiotemporal-pattern
#15
LETTER
Alojzija Hočevar, Aleš Ambrožič, Matija Tomšič
No abstract text is available yet for this article.
March 31, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33766895/interaction-between-the-stat4-rs11889341-t-risk-allele-and-smoking-confers-increased-risk-of-myocardial-infarction-and-nephritis-in-patients-with-systemic-lupus-erythematosus
#16
Sarah Reid, Niklas Hagberg, Johanna K Sandling, Andrei Alexsson, Pascal Pucholt, Christopher Sjöwall, Karoline Lerang, Andreas Jönsen, Iva Gunnarsson, Ann-Christine Syvänen, Anne Margrethe Troldborg, Anne Voss, Anders A Bengtsson, Øyvind Molberg, Søren Jacobsen, Elisabet Svenungsson, Lars Rönnblom, Dag Leonard
OBJECTIVE: To investigate how genetics influence the risk of smoking-related systemic lupus erythematosus (SLE) manifestations. METHODS: Patients with SLE (ndiscovery cohort =776, nreplication cohort =836) were genotyped using the 200K Immunochip single nucleotide polymorphisms (SNP) Array (Illumina) and a custom array. Sixty SNPs with SLE association (p<5.0×10-8 ) were analysed. Signal transducer and activator of transcription 4 (STAT4) activation was assessed in in vitro stimulated peripheral blood mononuclear cells from healthy controls (n=45)...
March 25, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33762266/correspondence-on-statistical-review-frequently-given-comments
#17
LETTER
Daisuke Waki, Masahiro Banno, Takashi Fujiwara
No abstract text is available yet for this article.
March 24, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33762265/response-to-correspondence-on-statistical-review-frequently-given-comments-by-waki-et-al
#18
Stian Lydersen
No abstract text is available yet for this article.
March 24, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33762264/immunogenicity-and-safety-of-anti-sars-cov-2-mrna-vaccines-in-patients-with-chronic-inflammatory-conditions-and-immunosuppressive-therapy-in-a-monocentric-cohort
#19
Ulf M Geisen, Dennis K Berner, Florian Tran, Melike Sümbül, Lena Vullriede, Maria Ciripoi, Hayley M Reid, Annika Schaffarzyk, Ann C Longardt, Jeanette Franzenburg, Paula Hoff, Jan H Schirmer, Rainald Zeuner, Anette Friedrichs, Andrea Steinbach, Christine Knies, Robert Dh Markewitz, Peter J Morrison, Sascha Gerdes, Stefan Schreiber, Bimba F Hoyer
INTRODUCTION: In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become a high priority. Persons at risk of severe disease, for example, those receiving immunosuppressive therapies for chronic inflammatory cdiseases (CIDs), are prioritised for vaccination. However, data concerning generation of protective antibody titres in immunosuppressed patients are scarce. Additionally, mRNA vaccines represent a new vaccine technology leading to increased insecurity especially in patients with CID...
March 24, 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33757969/correspondence-on-factors-associated-with-progression-to-inflammatory-arthritis-in-first-degree-relatives-of-individuals-with-ra-following-autoantibody-positive-screening-in-a-non-clinical-setting
#20
LETTER
Marc Scherlinger, Thierry Schaeverbeke
No abstract text is available yet for this article.
March 23, 2021: Annals of the Rheumatic Diseases
journal
journal
20039
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"